<p>Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events</p>

英夫利昔单抗 医学 银屑病 生物仿制药 不利影响 甲氨蝶呤 肿瘤坏死因子α 免疫学 皮肤病科 内科学
作者
Smriti Subedi,Yu Gong,Youdong Chen,Yuling Shi
出处
期刊:Drug Design Development and Therapy [Dove Medical Press]
卷期号:Volume 13: 2491-2502 被引量:57
标识
DOI:10.2147/dddt.s200147
摘要

Psoriasis is a chronic immune-mediated skin disease affecting multiple systems, and tumor necrosis factor-α (TNF-α) plays a significant role in the initiation and progression of the disease process. Psoriasis has a high prevalence rate in the Western world, especially in the USA and Australia; in China, although the prevalence rate is much lower, there is still a large number of patients suffering from psoriasis and its comorbidities. As TNF-α is thought to be crucial in the pathogenesis of psoriasis, specific therapy blocking TNF-α may be beneficial in the treatment of this disease. Infliximab, a murine-human monoclonal antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis, with better skin clearance and faster onset of action than topical medications such as methotrexate, narrow-band ultraviolet B, and calcipotriol. Lack of adherence to infliximab therapy is mainly due to loss of response (LOR) over time and adverse events, particularly because infusion reactions are usually encountered. Anti-infliximab antibody is thought to be responsible for the LOR and infusion reactions. However, the mechanism underlying the formation of anti-infliximab antibody and its side effects remains unclear. Further studies identifying patients at risk for LOR will probably help clinicians to select the right patients for anti-TNF-α therapy and to increase the durability of the treatment. This review discusses the efficacy of infliximab as demonstrated by various clinical trials, LOR to infliximab, combatting LOR, as well as the adverse events usually faced during the use of infliximab therapy and the infliximab biosimilar Remsima®. We hope that we can discover a better way to use infliximab in the therapy of psoriasis from the current research data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
paper reader完成签到,获得积分10
1秒前
呆呆完成签到 ,获得积分10
1秒前
纯真雁菱完成签到,获得积分10
4秒前
xuhanghang完成签到,获得积分10
7秒前
hhh完成签到,获得积分10
8秒前
皮皮蛙完成签到,获得积分10
9秒前
鸡蛋完成签到 ,获得积分10
13秒前
Xiaoxiao应助科研通管家采纳,获得10
13秒前
Xiaoxiao应助科研通管家采纳,获得10
13秒前
玩命的十三完成签到 ,获得积分10
14秒前
眰恦完成签到 ,获得积分10
15秒前
HY完成签到,获得积分10
15秒前
yulian完成签到,获得积分10
17秒前
17秒前
无与伦比完成签到 ,获得积分10
18秒前
独行者完成签到,获得积分10
20秒前
21秒前
蓝桉完成签到 ,获得积分10
21秒前
Yue完成签到 ,获得积分10
26秒前
GB完成签到 ,获得积分10
27秒前
长风与海浪完成签到 ,获得积分10
28秒前
无为完成签到 ,获得积分10
30秒前
Zo完成签到,获得积分10
31秒前
iwsaml完成签到 ,获得积分10
31秒前
SciEngineerX完成签到,获得积分10
32秒前
32秒前
不吃芹菜完成签到,获得积分0
33秒前
曾经小伙完成签到 ,获得积分10
33秒前
YANGMJ完成签到,获得积分10
34秒前
小杨完成签到,获得积分10
37秒前
38秒前
wu8577完成签到 ,获得积分10
42秒前
愛愛愛愛发布了新的文献求助10
43秒前
43秒前
kk完成签到,获得积分10
46秒前
sally发布了新的文献求助10
47秒前
听寒完成签到,获得积分10
48秒前
OhOHOh完成签到,获得积分10
49秒前
专注的翠彤完成签到,获得积分10
50秒前
木木三完成签到,获得积分20
51秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968578
求助须知:如何正确求助?哪些是违规求助? 3513391
关于积分的说明 11167428
捐赠科研通 3248822
什么是DOI,文献DOI怎么找? 1794499
邀请新用户注册赠送积分活动 875116
科研通“疑难数据库(出版商)”最低求助积分说明 804664